Essential Pharma, an international specialty pharma group, completed the acquisition of Renaissance Pharma, a clinical stage pharmaceutical company. Financial terms were not disclosed. “Essential Pharma is the right partner to take Hu14.18 forward. Having worked alongside Emma at EUSA Pharma, a company specialising in oncology and rare disease, I know that she and the Essential Pharma team have the experience and expertise to bring this important product to market and make it available for children with high-risk neuroblastoma," Lee Morley, Renaissance Pharma Chairman.